Ligand Pharma (LGND) Tops Q4 EPS by 53c ; Offers Guidance

Ligand Pharma (NASDAQ: LGND) reported Q4 EPS of $2.02, $0.53 better than the analyst estimate of $1.49. Revenue for the quarter came in at $59.66 million versus the consensus estimate of $55.59 million.

GUIDANCE:

Ligand Pharma sees FY2026 EPS of $8.00-$9.00, versus the consensus of $8.42. Ligand Pharma sees FY2026 revenue of $245-285 million, versus the consensus of $265.7 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.

You May Also Be Interested In

• Evercore ISI Upgrades The Macerich Company (MAC) to Outperform, 'improving balance sheet and accelerating FFO growth'
• Oppenheimer Reiterates Outperform Rating on Viking Therapeutic (VKTX)
• Citi lowers Hancock Whitney price target to $86